This result signifies that the patient has two copies of increased function alleles. Based on the genotype result this patient is predicted to be an ultrarapid metabolizer of CYP2B6 substrates. There is no reason to selectively adjust the dose of most medications that are metabolized by CYP2B6. Please consult a clinical pharmacist for more information about how CYP2B6 metabolic status influences drug selection and dosing.